Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 16/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.40 |
| ▸ | HTR3B | O95264 | 5/20 | 0.40 |
| ▸ | HTR3A | P46098 | 5/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061856 | 1.00 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7220613 | 0.83 | CHRNA7 (0.54) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7061274 | 0.83 | CHRNA7 (0.54) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7062847 | 0.82 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7061921 | 0.82 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7064143 | 0.81 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL6804367 | 0.81 | CHRNA7 (0.65) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7057901 | 0.81 | CHRNA7 (0.65) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7064071 | 0.81 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B | |
| SCHEMBL7063269 | 0.81 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNA4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-9650349-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-05-16 | — | — | US | disclosed |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-11-26 | — | — | US | disclosed |
| US-9029397-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-12 | — | — | US | disclosed |
| US-8921399-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-12-30 | — | — | US | disclosed |
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-02-28 | — | — | US | disclosed |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-08-09 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHRNA7 81/4885CHRNB2 85/4885CHRNA4 72/4885 |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHRNA7 81/4885CHRNB2 85/4885CHRNA4 72/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHRNA7 81/4885CHRNB2 85/4885CHRNA4 72/4885 |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHRNA7 81/4885CHRNB2 85/4885CHRNA4 72/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | CHRNA7 81/4885CHRNB2 85/4885CHRNA4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.